EII.F Eisai Co. Ltd

Healthcare Pharmaceuticals Frankfurt Exchange
28.01 EUR
Close of Nov 12, 2026
19.38 31.02
Market cap
EUR 7.91B
P/E
35.9x
P/B
1.56x
ROE
4.3%
Dividend yield
3.21%
Fundamental score
-

Ratios use the latest price and the fiscal year ending Mar 2026.

Is EII.F undervalued?

Graham number
Price28.01
Graham value17.73
Premium58.0%

EII.F trades 58.0% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Eisai Co. Ltd fundamental analysis

No fundamental analysis for Eisai Co. Ltd yet.

Eisai Co. Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Eisai Co. Ltd

Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aß) protofibrils; and Dayvigo, a novel small molecule compound. The company also provides prescription drugs; and over…

Full company profile